74 related articles for article (PubMed ID: 23099978)
21. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
22. Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma.
Kim KS; Min JK; Liang ZL; Lee K; Lee JU; Bae KH; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Choi MJ; Jo YS; Kim JM; Shong M
Clin Cancer Res; 2012 Jun; 18(11):3071-8. PubMed ID: 22472175
[TBL] [Abstract][Full Text] [Related]
23. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286
[TBL] [Abstract][Full Text] [Related]
24. [Molecular mechanism of Aurora kinase inhibitor PHA739358 in inhibited proliferation and induced apoptosis of breast cancer cells].
Zhang Y; Zhang B; Feng WH; Li YY; Cao XC
Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(1):45-9. PubMed ID: 22490658
[TBL] [Abstract][Full Text] [Related]
25. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
26. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
Catalano MG; Pugliese M; Poli R; Bosco O; Bertieri R; Fortunati N; Boccuzzi G
Oncol Rep; 2009 Feb; 21(2):515-21. PubMed ID: 19148530
[TBL] [Abstract][Full Text] [Related]
27. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex.
Lim YC; Cha YY
J Surg Oncol; 2011 Dec; 104(7):776-80. PubMed ID: 21725973
[TBL] [Abstract][Full Text] [Related]
28. Aurora kinases: new molecular targets in thyroid cancer therapy.
Baldini E; Sorrenti S; D'Armiento E; Prinzi N; Guaitoli E; Favoriti P; Gnessi L; Moretti C; Bianchini M; Alessandrini S; Catania A; De Antoni E; Ulisse S
Clin Ter; 2012 Nov; 163(6):e457-62. PubMed ID: 23306762
[TBL] [Abstract][Full Text] [Related]
29. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.
Salvatore G; Nappi TC; Salerno P; Jiang Y; Garbi C; Ugolini C; Miccoli P; Basolo F; Castellone MD; Cirafici AM; Melillo RM; Fusco A; Bittner ML; Santoro M
Cancer Res; 2007 Nov; 67(21):10148-58. PubMed ID: 17981789
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
31. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO).
Yin F; Giuliano AE; Van Herle AJ
Anticancer Res; 1999; 19(5B):4297-303. PubMed ID: 10628390
[TBL] [Abstract][Full Text] [Related]
32. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
Conroy A; Stockett DE; Walker D; Arkin MR; Hoch U; Fox JA; Hawtin RE
Cancer Chemother Pharmacol; 2009 Sep; 64(4):723-32. PubMed ID: 19169685
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
34. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
[TBL] [Abstract][Full Text] [Related]
35. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
Walsby E; Lazenby M; Pepper C; Burnett AK
Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
[TBL] [Abstract][Full Text] [Related]
36. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
37. Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway.
Zhong WB; Hsu SP; Ho PY; Liang YC; Chang TC; Lee WS
Biochem Pharmacol; 2011 Dec; 82(11):1663-72. PubMed ID: 21907187
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
39. The dietary flavonoid luteolin inhibits Aurora B kinase activity and blocks proliferation of cancer cells.
Xie F; Lang Q; Zhou M; Zhang H; Zhang Z; Zhang Y; Wan B; Huang Q; Yu L
Eur J Pharm Sci; 2012 Aug; 46(5):388-96. PubMed ID: 22449725
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Therapeutic Effects of Harmine on Anaplastic Thyroid Cancer Cells.
Baldini E; Cardarelli S; Campese AF; Lori E; Fallahi P; Virili C; Forte F; Pironi D; Di Matteo FM; Palumbo P; Costanzo ML; D'Andrea V; Centanni M; Sorrenti S; Antonelli A; Ulisse S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
